Metabolic syndrome has a high prevalence in the United States, and has been shown to be predictive of coronary heart disease and type 2 diabetes. In this presentation Dr Nesto will describe how levels of C-Reactive Protein (CRP), a marker of inflammation, can add prognostic information in patients with the metabolic syndrome, how interventions such as weight reduction and pharmacological agents reduce inflammation and improve components of the metabolic syndrome; and how to identify metabolic syndrome patients at high risk for developing cardiovascular disease and diabetes.

Copyright © 2004 MULTIWEBCAST "State-of-the-Art Webcast Services"

The participant will learn about the increased risk of cardiovascular disease and diabetes in metabolic sydrome patients, how to guage that risk, and what medical interventions may be used to improve inflammation and components of the metabolic syndrome.

Festa et al. Inflammation in the Prediabetic State Is Related to Increased Insulin Resistance Rather Than Decreased Insulin Secretion Circulation. 2003 Oct 14;108(15):1822-30.

Ford ES et al. Prevalence of the Metabolic Syndrome Among US Adults JAMA 2002; 287: 356-9.

Hu FB et al. Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes Diabetes Care. 2002 Jul;25(7):1129-34.

Lakka HM et al. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men JAMA. 2002;288:2709-2716

Meigs JB et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000 Jan 12;283(2):221-8.

Sattar N et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study Circulation 2003; 108: 414-9

Steven M. Haffner MDInsulin resistance, inflammation, and the prediabetic stateThe American Journal of Cardiology Volume 92, Issue 4, Supplement 1 , 18 August 2003, Pages 18-26

R. NestoC-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinedionesDiabetic MedicineVolume 21 Issue 8 Page 810 - August 2004

Melissa K. Cavaghan, David A. Ehrmann, Maria M. Byrne, and Kenneth S. Polonsky Treatment with the Oral Antidiabetic Agent Troglitazone Improves Cell Responses to Glucose in Subjects with Impaired Glucose ToleranceJ. Clin. Invest.Volume 100, Number 3, August 1997, 530-537

Hung YJ, Hsieh CH, Pei D, Kuo SW, Lee JT, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.Clin Endocrinol (Oxf). 2005 Jan;62(1):85-91.